TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin

2015 ◽  
Vol 138 (3) ◽  
pp. 627-633 ◽  
Author(s):  
J. Erriquez ◽  
P. Becco ◽  
M. Olivero ◽  
R. Ponzone ◽  
F. Maggiorotto ◽  
...  
Keyword(s):  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Gene Copy ◽  
Ovarian Cancers ◽  
Top2a Gene

Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial

2019 ◽  
Vol 152 (1) ◽  
pp. 68-75 ◽  
Author(s):  
Clémence Romeo ◽  
Florence Joly ◽  
Isabelle Ray-Coquard ◽  
Claude El Kouri ◽  
Anne Mercier-Blas ◽  
...  
Keyword(s):  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Phase Ib ◽  
Platinum Sensitive ◽  
Ovarian Cancers

Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers

2011 ◽  
Vol 122 (2) ◽  
pp. 233-237 ◽  
Author(s):  
Kazuya Kudoh ◽  
Masashi Takano ◽  
Hiroko Kouta ◽  
Ryoko Kikuchi ◽  
Tsunekazu Kita ◽  
...  
Keyword(s):  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Ovarian Cancers
Sign in / Sign up

Export Citation Format

Share Document